Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (271-280 of 471) with videos related to

Pageof 48
Sort By:
European Journal of Heart Failure|March 4, 2010
Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trialShannon M Dunlay, Mihai Gheorghiade, Kimberly J Reid, et al.
European Journal of Heart Failure|December 12, 2018
The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetesRasmus Rørth, Pardeep S Jhund, Søren L Kristensen, et al.
European Journal of Heart Failure|August 10, 2005
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practiceJohn McMurray, Alain Cohen-Solal, Rainer Dietz, et al.
Circulation. Heart Failure|December 4, 2013
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)Patrick Rossignol, Daniela Dobre, John J V McMurray, et al.
European Journal of Heart Failure|April 9, 2013
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)John J V McMurray, Milton Packer, Akshay S Desai, et al.
Journal of Cardiac Failure|June 8, 2013
Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptanPaul J Hauptman, John Burnett, Mihai Gheorghiade, et al.
Circulation. Heart Failure|April 17, 2014
Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trialRobert J Mentz, Stephen J Greene, Andrew P Ambrosy, et al.
Circulation. Heart Failure|October 12, 2012
Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trialMuthiah Vaduganathan, Andrew P Ambrosy, Stephen J Greene, et al.
Lancet (London, England)|August 18, 2009
Albuminuria in chronic heart failure: prevalence and prognostic importanceColette E Jackson, Scott D Solomon, Hertzel C Gerstein, et al.
Circulation|October 7, 2004
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programScott D Solomon, Duolao Wang, Peter Finn, et al.
Pageof 48

Showing results (271-280 of 471) with videos related to

Sort By:
Pageof 48
European Journal of Heart Failure|March 4, 2010
Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trialShannon M Dunlay, Mihai Gheorghiade, Kimberly J Reid, et al.
European Journal of Heart Failure|December 12, 2018
The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetesRasmus Rørth, Pardeep S Jhund, Søren L Kristensen, et al.
European Journal of Heart Failure|August 10, 2005
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practiceJohn McMurray, Alain Cohen-Solal, Rainer Dietz, et al.
Circulation. Heart Failure|December 4, 2013
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)Patrick Rossignol, Daniela Dobre, John J V McMurray, et al.
European Journal of Heart Failure|April 9, 2013
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)John J V McMurray, Milton Packer, Akshay S Desai, et al.
Journal of Cardiac Failure|June 8, 2013
Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptanPaul J Hauptman, John Burnett, Mihai Gheorghiade, et al.
Circulation. Heart Failure|April 17, 2014
Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trialRobert J Mentz, Stephen J Greene, Andrew P Ambrosy, et al.
Circulation. Heart Failure|October 12, 2012
Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trialMuthiah Vaduganathan, Andrew P Ambrosy, Stephen J Greene, et al.
Lancet (London, England)|August 18, 2009
Albuminuria in chronic heart failure: prevalence and prognostic importanceColette E Jackson, Scott D Solomon, Hertzel C Gerstein, et al.
Circulation|October 7, 2004
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programScott D Solomon, Duolao Wang, Peter Finn, et al.
Pageof 48